Iga Nephropathy Igan clinical trials

Explore recruiting iga nephropathy igan clinical trials.

Recruiting iga nephropathy igan studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Iga Nephropathy Igan trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Early start corticosteroids versus standard care (RASBs followed by corticosteroids) for proteinuria in Immunoglobulin A Nephropathy (IgAN) patients with active renal lesions identified by kidney biopsy and RASBs combined with corticosteroids versus sodium-glucose cotransporter2 inhibitor combined with RASBs for proteinuria and renal function in IgAN patients with chronic renal lesions identified by kidney biopsy. A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY BIOPSY FINDINGS IN IgAN PATIENTS (CLIgAN)

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)

Germany, Czechia, Belgium, Greece, Poland, Denmark +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN

Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Iga Nephropathy Igan trials by city

Iga Nephropathy Igan in Toronto Iga Nephropathy Igan in Vancouver Iga Nephropathy Igan in Montreal Iga Nephropathy Igan in Calgary Iga Nephropathy Igan in Edmonton Iga Nephropathy Igan in Ottawa Iga Nephropathy Igan in Winnipeg Iga Nephropathy Igan in Quebec City Iga Nephropathy Igan in Hamilton Iga Nephropathy Igan in Kitchener Iga Nephropathy Igan in London Iga Nephropathy Igan in Halifax Iga Nephropathy Igan in New York Iga Nephropathy Igan in Los Angeles Iga Nephropathy Igan in Chicago Iga Nephropathy Igan in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease